ACMG, NSGC, and others in the genetics community are monitoring whether the widely used online clinical genetics database could be at risk.
With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.
On the heels of its acquisition by Ocuphire Pharma, Opus is planning next steps for its Leber congenital amaurosis type 5 gene therapy.
The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.
UK's NICE Approves J&J's Balversa for FGFR3-Altered Urothelial Cancer
The recommendation was based on results from the Phase III THOR trial, which compared Balversa to chemotherapy.